Fluvoxamine increased glutamate release by activating both 5-HT(3) and sigma-1 receptors in prelimbic cortex of chronic restraint stress C57BL/6 mice.
Emerging evidence from therapeutic trials in humans and animal models suggests that in the treatment of depression, antidepressants play a role by targeting the glutamatergic system. Fluvoxamine is one of the widely used SSRIs which has been considered to target monoamine neurotransmitter reuptake mechanisms. However, whether fluvoxamine has an effect on the glutamate release is still unclear. The present experiment studied the effect of fluvoxamine on presynaptic glutamate release in prelimbic cortex, both in control C57BL/6 mice and chronic restraint stress C57BL/6 mice, and further investigated the mechanism underlying this effect by using patch clamp, on-line fluorimetry, pharmacological approaches combined with other techniques. The results showed that fluvoxamine increased the glutamate release in the depression model mice but it had no effect on the glutamate release in the control mice. The mechanism underlying these effects in depression model mice was that, fluvoxamine firstly activated presynaptic 5-HT(3) receptors, which transiently increased the Ca(2+) concentration. The increase of Ca(2+) concentration via 5-HT(3) receptors caused the activation of sigma-1 receptors, which were activated by fluvoxamine. The activation of sigma-1 receptors increased the intrasynaptosomal Ca(2+) concentration significantly through the outflow of endoplasmic reticulum calcium and finally activated PKC. These results suggested that fluvoxamine may have a selective effect and different mechanism based on the condition of animal.
Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Yingmei
Y
Fu
Shunying
S
Yu
Xiaoyun
X
Guo
Xia
X
Li
Ting
T
Li
Huafang
H
Li
Yi
Y
Dong
D000818:Animals; D053119:Benzophenanthridines / Q000494:pharmacology; D002118:Calcium / Q000378:metabolism; D002121:Calcium Channel Blockers / Q000494:pharmacology; D002540:Cerebral Cortex / Q000187:drug effects / Q000378:metabolism*; D002908:Chronic Disease; D004533:Egtazic Acid / Q000494:pharmacology; D004721:Endoplasmic Reticulum / Q000187:drug effects / Q000378:metabolism; D016666:Fluvoxamine / Q000008:administration & dosage / Q000494:pharmacology*; D018698:Glutamic Acid / Q000378:metabolism*; D008032:Limbic System / Q000187:drug effects / Q000378:metabolism*; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D008954:Models, Biological; D011493:Protein Kinase C / Q000378:metabolism; D044406:Receptors, Serotonin, 5-HT3 / Q000378:metabolism*; D017480:Receptors, sigma / Q000819:agonists / Q000378:metabolism*; D012149:Restraint, Physical; D058831:Serotonin 5-HT3 Receptor Antagonists / Q000494:pharmacology; D013312:Stress, Physiological / Q000187:drug effects*; D013569:Synapses / Q000187:drug effects / Q000378:metabolism; D013574:Synaptosomes / Q000187:drug effects / Q000378:metabolism; D000097605:Sigma-1 Receptor
D053119:Benzophenanthridines; D002118:Calcium; D002121:Calcium Channel Blockers; D004533:Egtazic Acid; D016666:Fluvoxamine; D018698:Glutamic Acid; D011493:Protein Kinase C; D044406:Receptors, Serotonin, 5-HT3; D017480:Receptors, sigma; D058831:Serotonin 5-HT3 Receptor Antagonists; D000097605:Sigma-1 Receptor; C016299:chelerythrine